Polymorphisms of Vitamin D Receptor and Survival in Early-Stage Non-Small Cell Lung Cancer Patients
-
2006/11/01
-
Details
-
Personal Author:Asomaning K ; Christiani, David C. ; Giovannucci E ; Heist RS ; Liu G ; Lynch TJ ; Neuberg DS ; Su L ; Wain JC ; Zhou W
-
Description:Our previous analysis suggested that surgery season in the summer time and high vitamin D intake are associated with improved survival in early-stage non-small cell lung cancer (NSCLC) patients. Here, we investigated the associations of vitamin D receptor (VDR) polymorphisms of Cdx-2 G>A, FokI C>T, and BsmI C>T with overall survival (OS) and recurrence-free survival (RFS) in 373 early-stage NSCLC patients. The data were analyzed using log-rank test and Cox proportional hazards models. The median follow-up time was 71 months (range, 0.1-140 months), with 186 deaths and 127 recurrences. There was no association between VDR polymorphisms and survival, overall or among adenocarcinoma patients. Among squamous cell carcinoma (SCC) patients, the G/A+A/A genotype group of the Cdx-2 polymorphism was associated with better OS: the 5-year OS rates were 41% [95% confidence interval (95% CI), 28-53] for the G/G and 55% (95% CI, 39-71) for the G/A+A/A genotypes, respectively (P = 0.04, log-rank test), with the adjusted hazard ratio of 0.56 (95% CI, 0.33-0.95) for G/A+A/A versus G/G. For the joint effects of the three polymorphisms, subjects with two or more "protective" alleles have better OS among SCC patients, with the adjusted hazard ratios of 0.20 (95% CI, 0.09-0.48), 0.40 (95% CI, 0.19-0.87), and 0.43 (95% CI, 0.19-0.97), respectively, for subjects with two, three, and four or more "protective" alleles when compared with subjects with zero or one "protective" allele (P(trend) = 0.71). Similar associations were found in haplotype analysis and for RFS among SCC patients. In conclusion, VDR polymorphisms may be associated with improved survival among SCC patients of early-stage NSCLC. [Description provided by NIOSH]
-
Subjects:
-
Keywords:
-
ISSN:1055-9965
-
Document Type:
-
Funding:
-
Genre:
-
Place as Subject:
-
CIO:
-
Topic:
-
Location:
-
Volume:15
-
Issue:11
-
NIOSHTIC Number:nn:20060030
-
Citation:Cancer Epidemiol Biomark Prev 2006 Nov; 15(11):2239-2245
-
Contact Point Address:Wei Zhou, Occupational Health Program, Harvard School of Public Health, 665 Huntington Avenue, Boston, MA 02115
-
Email:wzhou@hsph.harvard.edu
-
Federal Fiscal Year:2007
-
Performing Organization:Harvard School of Public Health
-
Peer Reviewed:True
-
Start Date:20050701
-
Source Full Name:Cancer Epidemiology, Biomarkers & Prevention
-
End Date:20280630
-
Collection(s):
-
Main Document Checksum:urn:sha-512:986394743761379b2cf53047b9b8078b3a7a07fc89f41ec6342cf94f35c76f0edbeb4d1b248b96a28b6e98524d32b6325aaa61a8ef88beb95bbc544ef24a583c
-
Download URL:
-
File Type:
ON THIS PAGE
CDC STACKS serves as an archival repository of CDC-published products including
scientific findings,
journal articles, guidelines, recommendations, or other public health information authored or
co-authored by CDC or funded partners.
As a repository, CDC STACKS retains documents in their original published format to ensure public access to scientific information.
As a repository, CDC STACKS retains documents in their original published format to ensure public access to scientific information.
You May Also Like